Goto Tetsuo, Fujigaki Yoshihide, Sun Di Fei, Yamamoto Tatsuo, Hishida Akira
First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, 431-3192 Hamamatsu, Japan.
Virchows Arch. 2004 Apr;444(4):362-74. doi: 10.1007/s00428-004-0977-5. Epub 2004 Feb 24.
Microvascular hyperpermeability to plasma proteins via vascular endothelial growth factor (VEGF) with endothelial nitric oxide synthase (eNOS) induction may contribute to wound healing through matrix remodeling. However, vascular hyperpermeability is not examined in acute renal failure (ARF), a unique form of wound healing. Subcutaneous injection of gentamicin (400 mg/kg per day for 2 days in divided doses every 8 h) in rats increased serum creatinine levels and induced tubular damage, which peaked at day 6, after the last gentamicin injection. Ki67-positive regenerating proximal tubules (PTs) peaked in number at day 6 and almost covered the bare tubular basement membrane (TBM) by day 10. Staining of fibrinogen and plasma fibronectin began to increase in the peritubular regions as early as day 0, steadily increased in TBM and tubular lumen until day 6 and then decreased. Hyperpermeable peritubular capillaries were identified by extravasation of perfused-fluoresceinated dextran (both 70 kDa and 250 kDa) into peritubular regions as early as day 0 and prominently into TBM and tubular lumen at day 6. Electron microscopy further suggested the intraendothelial pathway of dextran. Immunoreactive VEGF increased in the damaged and regenerating PTs. Immunoreactive VEGF receptors-1 and -2 did not change, but immunoreactive eNOS increased in the peritubular capillaries after induction of ARF. Western blotting for VEGF and eNOS supported the immunostaining findings. In addition, we assessed the effects of NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME) on vascular hyperpermeability during the recovery phase of this model. Treatment with L-NAME (s.c. at a dose of 100 mg/kg/day from day 3 to day 6) decreased extravasation of perfused-250-kDa dextran and significantly inhibited the regenerative repair of PTs at day 6 when compared with vehicle-treated rats. In conclusion, plasma protein extravasation occurred, leading to matrix remodeling, such as the process of wound healing during the tubular repair in gentamicin-induced ARF. Since VEGF-induced vascular hyperpermeability may depend on NO production, VEGF/VEGF receptor system with eNOS induction might be responsible for this process.
通过血管内皮生长因子(VEGF)介导并诱导内皮型一氧化氮合酶(eNOS)产生的微血管对血浆蛋白的高通透性,可能通过基质重塑促进伤口愈合。然而,在急性肾衰竭(ARF)这种独特的伤口愈合形式中,血管高通透性尚未得到研究。给大鼠皮下注射庆大霉素(400mg/kg/天,分剂量每8小时注射一次,共2天)可使血清肌酐水平升高并诱导肾小管损伤,在最后一次注射庆大霉素后第6天达到峰值。Ki67阳性的再生近端肾小管(PTs)数量在第6天达到峰值,到第10天时几乎覆盖了裸露的肾小管基底膜(TBM)。早在第0天,肾小管周围区域的纤维蛋白原和血浆纤连蛋白染色就开始增加,在TBM和肾小管管腔中持续增加直至第6天,然后下降。早在第0天,通过灌注荧光标记的葡聚糖(70kDa和250kDa)渗入肾小管周围区域就可确定肾小管周围毛细血管的高通透性,在第6天时显著渗入TBM和肾小管管腔。电子显微镜进一步提示了葡聚糖的内皮内途径。受损和再生的PTs中免疫反应性VEGF增加。免疫反应性VEGF受体-1和-2没有变化,但在ARF诱导后,肾小管周围毛细血管中免疫反应性eNOS增加。VEGF和eNOS的蛋白质免疫印迹法支持了免疫染色结果。此外,我们评估了NOS抑制剂N-硝基-L-精氨酸甲酯(L-NAME)对该模型恢复期血管高通透性的影响。与给予赋形剂处理的大鼠相比,用L-NAME处理(从第3天至第6天皮下注射,剂量为100mg/kg/天)可减少灌注的250kDa葡聚糖的渗出,并在第6天时显著抑制PTs的再生修复。总之,发生了血浆蛋白渗出,导致基质重塑,如庆大霉素诱导的ARF肾小管修复过程中的伤口愈合过程。由于VEGF诱导的血管高通透性可能依赖于NO的产生,VEGF/VEGF受体系统与eNOS的诱导可能是这一过程的原因。